Prospects of the use of bacteriophage-based virus-like particles in the creation of anthrax vaccines
The profitability of vaccine production is less than that of other pharmaceutical goods worldwide. Thus, the cost of the vaccine substance determines the range of vaccines available for use. This is of particular importance for veterinary vaccines. In this review, we have surveyed the published data...
Gespeichert in:
| Veröffentlicht in: | Applied biochemistry and microbiology 2016-12, Vol.52 (9), p.818-827 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 827 |
|---|---|
| container_issue | 9 |
| container_start_page | 818 |
| container_title | Applied biochemistry and microbiology |
| container_volume | 52 |
| creator | Letarov, A. V. Biryukova, Yu. K. Epremyan, A. S. Shevelev, A. B. |
| description | The profitability of vaccine production is less than that of other pharmaceutical goods worldwide. Thus, the cost of the vaccine substance determines the range of vaccines available for use. This is of particular importance for veterinary vaccines. In this review, we have surveyed the published data on exploited vaccines and concluded that the immunogenicity of antigen substances based on whole virions is higher than that of soluble antigens. The physiological basis of this phenomenon remains unknown; however, it may explain why most of the described recombinant vaccines have not yet been put into practice. All practically implemented antiviral vaccines (except that for hepatitis B) are based on viral substances produced by conventional cultural technologies. In light of this observation, an approach to the development of a universal platform for recombinant vaccines produced in the form of virus-like particles is suggested. To this end, a technique of designing fused bifunctional derivatives of bacteriophage proteins containing antigens of interest should be involved. The approach is depicted with the use of the protective anthrax antigen, a conventional vaccine antigen. |
| doi_str_mv | 10.1134/S0003683816090040 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1877833300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4313325861</sourcerecordid><originalsourceid>FETCH-LOGICAL-c301t-b77f970bcd89590576476854a340116dd137bf0699d0f893ee61ef4c485488d33</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMouK7-AG8FL16qk02bj6MsfsGCgnouaTrdzdpta5Iu-u9NXQ-ieJoZ5nmG4SXklMIFpSy7fAIAxiWTlIMCyGCPTGIrUwazbJ9MxnU67g_JkffrOCou1YRUj67zPZrgk65OwgqTwePYltoEdLbrV3qJaak9VsnWusGnjX3FpNcuWNOgT2z7pRmHOtiuHV3dhpXT78lWG2Nb9MfkoNaNx5PvOiUvN9fP87t08XB7P79apIYBDWkpRK0ElKaSKleQC54JLvNMswwo5VVFmShr4EpVUEvFEDnFOjNZZKSsGJuS893d3nVvA_pQbKw32DS6xW7wBZVCSMZYzGJKzn6h625wbfwuUlwoRlmeR4ruKBNT8g7rond2o91HQaEYcy_-5B6d2c7xkW2X6H5c_lf6BGlkgzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1867931355</pqid></control><display><type>article</type><title>Prospects of the use of bacteriophage-based virus-like particles in the creation of anthrax vaccines</title><source>Springer Online Journals Complete</source><creator>Letarov, A. V. ; Biryukova, Yu. K. ; Epremyan, A. S. ; Shevelev, A. B.</creator><creatorcontrib>Letarov, A. V. ; Biryukova, Yu. K. ; Epremyan, A. S. ; Shevelev, A. B.</creatorcontrib><description>The profitability of vaccine production is less than that of other pharmaceutical goods worldwide. Thus, the cost of the vaccine substance determines the range of vaccines available for use. This is of particular importance for veterinary vaccines. In this review, we have surveyed the published data on exploited vaccines and concluded that the immunogenicity of antigen substances based on whole virions is higher than that of soluble antigens. The physiological basis of this phenomenon remains unknown; however, it may explain why most of the described recombinant vaccines have not yet been put into practice. All practically implemented antiviral vaccines (except that for hepatitis B) are based on viral substances produced by conventional cultural technologies. In light of this observation, an approach to the development of a universal platform for recombinant vaccines produced in the form of virus-like particles is suggested. To this end, a technique of designing fused bifunctional derivatives of bacteriophage proteins containing antigens of interest should be involved. The approach is depicted with the use of the protective anthrax antigen, a conventional vaccine antigen.</description><identifier>ISSN: 0003-6838</identifier><identifier>EISSN: 1608-3024</identifier><identifier>DOI: 10.1134/S0003683816090040</identifier><language>eng</language><publisher>Moscow: Pleiades Publishing</publisher><subject>Anthrax ; Atoms & subatomic particles ; Bacteria ; Biochemistry ; Biologicals Technology ; Biomedical and Life Sciences ; Hepatitis B virus ; Immunogenicity ; Life Sciences ; Medical Microbiology ; Microbiology ; Vaccines ; Viruses</subject><ispartof>Applied biochemistry and microbiology, 2016-12, Vol.52 (9), p.818-827</ispartof><rights>Pleiades Publishing, Inc. 2016</rights><rights>Applied Biochemistry and Microbiology is a copyright of Springer, 2016.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c301t-b77f970bcd89590576476854a340116dd137bf0699d0f893ee61ef4c485488d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1134/S0003683816090040$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1134/S0003683816090040$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids></links><search><creatorcontrib>Letarov, A. V.</creatorcontrib><creatorcontrib>Biryukova, Yu. K.</creatorcontrib><creatorcontrib>Epremyan, A. S.</creatorcontrib><creatorcontrib>Shevelev, A. B.</creatorcontrib><title>Prospects of the use of bacteriophage-based virus-like particles in the creation of anthrax vaccines</title><title>Applied biochemistry and microbiology</title><addtitle>Appl Biochem Microbiol</addtitle><description>The profitability of vaccine production is less than that of other pharmaceutical goods worldwide. Thus, the cost of the vaccine substance determines the range of vaccines available for use. This is of particular importance for veterinary vaccines. In this review, we have surveyed the published data on exploited vaccines and concluded that the immunogenicity of antigen substances based on whole virions is higher than that of soluble antigens. The physiological basis of this phenomenon remains unknown; however, it may explain why most of the described recombinant vaccines have not yet been put into practice. All practically implemented antiviral vaccines (except that for hepatitis B) are based on viral substances produced by conventional cultural technologies. In light of this observation, an approach to the development of a universal platform for recombinant vaccines produced in the form of virus-like particles is suggested. To this end, a technique of designing fused bifunctional derivatives of bacteriophage proteins containing antigens of interest should be involved. The approach is depicted with the use of the protective anthrax antigen, a conventional vaccine antigen.</description><subject>Anthrax</subject><subject>Atoms & subatomic particles</subject><subject>Bacteria</subject><subject>Biochemistry</subject><subject>Biologicals Technology</subject><subject>Biomedical and Life Sciences</subject><subject>Hepatitis B virus</subject><subject>Immunogenicity</subject><subject>Life Sciences</subject><subject>Medical Microbiology</subject><subject>Microbiology</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0003-6838</issn><issn>1608-3024</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kE1LxDAQhoMouK7-AG8FL16qk02bj6MsfsGCgnouaTrdzdpta5Iu-u9NXQ-ieJoZ5nmG4SXklMIFpSy7fAIAxiWTlIMCyGCPTGIrUwazbJ9MxnU67g_JkffrOCou1YRUj67zPZrgk65OwgqTwePYltoEdLbrV3qJaak9VsnWusGnjX3FpNcuWNOgT2z7pRmHOtiuHV3dhpXT78lWG2Nb9MfkoNaNx5PvOiUvN9fP87t08XB7P79apIYBDWkpRK0ElKaSKleQC54JLvNMswwo5VVFmShr4EpVUEvFEDnFOjNZZKSsGJuS893d3nVvA_pQbKw32DS6xW7wBZVCSMZYzGJKzn6h625wbfwuUlwoRlmeR4ruKBNT8g7rond2o91HQaEYcy_-5B6d2c7xkW2X6H5c_lf6BGlkgzw</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Letarov, A. V.</creator><creator>Biryukova, Yu. K.</creator><creator>Epremyan, A. S.</creator><creator>Shevelev, A. B.</creator><general>Pleiades Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20161201</creationdate><title>Prospects of the use of bacteriophage-based virus-like particles in the creation of anthrax vaccines</title><author>Letarov, A. V. ; Biryukova, Yu. K. ; Epremyan, A. S. ; Shevelev, A. B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c301t-b77f970bcd89590576476854a340116dd137bf0699d0f893ee61ef4c485488d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anthrax</topic><topic>Atoms & subatomic particles</topic><topic>Bacteria</topic><topic>Biochemistry</topic><topic>Biologicals Technology</topic><topic>Biomedical and Life Sciences</topic><topic>Hepatitis B virus</topic><topic>Immunogenicity</topic><topic>Life Sciences</topic><topic>Medical Microbiology</topic><topic>Microbiology</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Letarov, A. V.</creatorcontrib><creatorcontrib>Biryukova, Yu. K.</creatorcontrib><creatorcontrib>Epremyan, A. S.</creatorcontrib><creatorcontrib>Shevelev, A. B.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Applied biochemistry and microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Letarov, A. V.</au><au>Biryukova, Yu. K.</au><au>Epremyan, A. S.</au><au>Shevelev, A. B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospects of the use of bacteriophage-based virus-like particles in the creation of anthrax vaccines</atitle><jtitle>Applied biochemistry and microbiology</jtitle><stitle>Appl Biochem Microbiol</stitle><date>2016-12-01</date><risdate>2016</risdate><volume>52</volume><issue>9</issue><spage>818</spage><epage>827</epage><pages>818-827</pages><issn>0003-6838</issn><eissn>1608-3024</eissn><abstract>The profitability of vaccine production is less than that of other pharmaceutical goods worldwide. Thus, the cost of the vaccine substance determines the range of vaccines available for use. This is of particular importance for veterinary vaccines. In this review, we have surveyed the published data on exploited vaccines and concluded that the immunogenicity of antigen substances based on whole virions is higher than that of soluble antigens. The physiological basis of this phenomenon remains unknown; however, it may explain why most of the described recombinant vaccines have not yet been put into practice. All practically implemented antiviral vaccines (except that for hepatitis B) are based on viral substances produced by conventional cultural technologies. In light of this observation, an approach to the development of a universal platform for recombinant vaccines produced in the form of virus-like particles is suggested. To this end, a technique of designing fused bifunctional derivatives of bacteriophage proteins containing antigens of interest should be involved. The approach is depicted with the use of the protective anthrax antigen, a conventional vaccine antigen.</abstract><cop>Moscow</cop><pub>Pleiades Publishing</pub><doi>10.1134/S0003683816090040</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-6838 |
| ispartof | Applied biochemistry and microbiology, 2016-12, Vol.52 (9), p.818-827 |
| issn | 0003-6838 1608-3024 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1877833300 |
| source | Springer Online Journals Complete |
| subjects | Anthrax Atoms & subatomic particles Bacteria Biochemistry Biologicals Technology Biomedical and Life Sciences Hepatitis B virus Immunogenicity Life Sciences Medical Microbiology Microbiology Vaccines Viruses |
| title | Prospects of the use of bacteriophage-based virus-like particles in the creation of anthrax vaccines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A35%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospects%20of%20the%20use%20of%20bacteriophage-based%20virus-like%20particles%20in%20the%20creation%20of%20anthrax%20vaccines&rft.jtitle=Applied%20biochemistry%20and%20microbiology&rft.au=Letarov,%20A.%20V.&rft.date=2016-12-01&rft.volume=52&rft.issue=9&rft.spage=818&rft.epage=827&rft.pages=818-827&rft.issn=0003-6838&rft.eissn=1608-3024&rft_id=info:doi/10.1134/S0003683816090040&rft_dat=%3Cproquest_cross%3E4313325861%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1867931355&rft_id=info:pmid/&rfr_iscdi=true |